Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Acetohexamide: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 457487337 of page Acetohexamide for the Chem/Drugbox validation project (updated: 'DrugBank'). |
CrafterNova (talk | contribs) →Risks: removed instructional language per MOS:INSTRUCT Tags: Mobile edit Mobile web edit Advanced mobile edit |
||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Acetohexamide|oldid=457487337}} 457487337] of page [[Acetohexamide]] with values updated to verified values.}} |
|||
{{distinguish|acetazolamide}} |
|||
{{Drugbox |
{{Drugbox |
||
| |
| Watchedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 477239096 |
||
| IUPAC_name = 4- |
| IUPAC_name = 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea |
||
| ⚫ | |||
4-acetyl-''N''-(cyclohexylcarbamoyl)benzenesulfonamide |
|||
| ⚫ | |||
| image2 = Acetohexamide_ball-and-stick.png |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Dymelor |
| tradename = Dymelor |
||
| Line 13: | Line 16: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
| Line 19: | Line 21: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 6793 |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 968-81-0 |
| CAS_number = 968-81-0 |
||
| Line 28: | Line 29: | ||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = 1989 |
| PubChem = 1989 |
||
| DrugBank_Ref = {{drugbankcite| |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = DB00414 |
| DrugBank = DB00414 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| Line 40: | Line 41: | ||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 1589 |
| ChEMBL = 1589 |
||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=15 | H=20 |
| C=15 | H=20 |
||
| N=2 | O=4 |
|||
| S=1 |
|||
| molecular_weight = 324.395 g/mol |
|||
| smiles = O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(C(=O)C)cc2 |
| smiles = O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(C(=O)C)cc2 |
||
| InChI = 1/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) |
|||
| InChIKey = VGZSUPCWNCWDAN-UHFFFAOYAN |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) |
| StdInChI = 1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = VGZSUPCWNCWDAN-UHFFFAOYSA-N |
| StdInChIKey = VGZSUPCWNCWDAN-UHFFFAOYSA-N |
||
| melting_point = 188 |
|||
| melting_high = 190 |
|||
}} |
}} |
||
'''Acetohexamide''' (trade name '''Dymelor''') is a first-generation [[sulfonylurea]] [[medication]] used to treat [[diabetes mellitus type 2]], particularly in people whose diabetes cannot be controlled by diet alone.<ref name="pmid14216839">{{cite journal | vauthors = Montgomery DA | title = Current Therapeutics. CCII. Acetohexamide | journal = The Practitioner | volume = 193 | issue = | pages = 555–60 | date = October 1964 | pmid = 14216839 | doi = | url = }}</ref> |
|||
==Mechanism of action== |
|||
Acetohexamide bind to an [[ATP-sensitive potassium channel|ATP-sensitive K<sup>+</sup>]] (K<sub>ATP</sub>) channel on the cell membrane of [[pancreatic beta cell]]s. This inhibits the out flux of [[potassium in biology|potassium]], which causes the [[membrane potential]] to become more positive. This depolarization in turn opens [[voltage-gated calcium channel]]s. The rise in intracellular [[calcium in biology|calcium]] leads to increased fusion of [[Granule_(cell_biology)#Insulin_granules_in_beta_cells|insulin granulae]] with the cell membrane, and therefore increased secretion of insulin.<ref>{{cite web | title = Acetohexamide | url = https://go.drugbank.com/drugs/DB00414 | work = DrugBank }}</ref> |
|||
==Risks== |
|||
Oral hypoglycemic drugs, including acetohexamide, have been associated with increased [[cardiovascular]] mortality. Qualified healthcare professionals should consulted for possible risks, benefits, and alternatives of using this drug for treatment of type 2 diabetes.<ref>{{cite web | title = Acetohexamide | url = https://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682478.html | work = Medline Plus | archive-url = https://web.archive.org/web/20050911024428/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682478.html | archive-date = 11 September 2005 }}</ref> |
|||
==References== |
|||
{{Reflist}} |
|||
{{Oral hypoglycemics}} |
|||
{{Ion channel modulators}} |
|||
[[Category:Potassium channel blockers]] |
|||
[[Category:1-(Benzenesulfonyl)-3-cyclohexylureas]] |
|||
[[Category:Aromatic ketones]] |
|||
{{Gastrointestinal-drug-stub}} |
|||